Detalles de la búsqueda
1.
Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics.
Mod Rheumatol
; 32(4): 718-727, 2022 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34918129
2.
Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan.
J Gastroenterol Hepatol
; 36(8): 2091-2100, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33450057
3.
Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies.
Drug Saf
; 46(10): 991-1005, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37700154
4.
Safety, efficacy, and drug survival of the infliximab biosimilar CT-P13 in post-marketing surveillance of Japanese patients with psoriasis.
J Dermatol
; 49(10): 957-969, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35799412
5.
Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice.
Intest Res
; 17(4): 504-515, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31422647
Resultados
1 -
5
de 5
1
Próxima >
>>